Moreover, the WL achieved in people with T2D and/or obesity at phase 3 clinical trials with the recently approved for T2D management dual agonist tirzepatide suggests that combination of gut hormones may lead to additional WL compared with GLP-1 RAs alone. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.